Answers are grounded in this paper and cite their sources.
Demonstrates a method to model antibiotic drug behavior in critically ill adults, suggesting future applications in PK/PD studies.
Published antibiotic pharmacokinetic/pharmacodynamic (PK/PD) data is frequently not readily applicable for simulation due to the dispersion of pertinent information among diverse and incomplete sources. We created a component-level evidence-composite procedure to transform fragmented ceftazidime-avibactam pharmacokinetic/pharmacodynamic evidence into traceable, scenario-compatible, simulation-ready inputs. Six source packages were disaggregated into reusable components, clearance relationships, variability, protein binding, pharmacokinetic/pharmacodynamic targets, minimum inhibitory concentration distributions, and calibration anchors, each designated with origin, transformation, and review-state labels, while maintaining missingness instead of covertly imputing values. The primary scenario modeled critically ill adults without renal replacement therapy receiving continuous-infusion ceftazidime-avibactam. Ceftazidime and avibactam were modeled as separate pharmacokinetic components and evaluated jointly. The simulation included 100,000 virtual subjects across five EKFC renal-function classes, MIC-weighted cumulative fraction of response (CFR) analysis, calibration against published benchmarks (69/72 rows passing), convergence assessment, multi-seed reproducibility, and global and probabilistic sensitivity analyses. Avibactam-related inputs, clearance, interindividual variability, and unbound fraction, were identified as dominant drivers of joint target attainment uncertainty. No regimen-distribution pair met the criterion for full robustness under probabilistic stress testing. This workflow demonstrates that incomplete antimicrobial pharmacometric publications can be converted into reproducible, simulation-ready evidence components and should be interpreted as a methodological proof of concept, not a clinical dosing recommendation.
No takes yet. Share an insight, caveat, or question.
vahhab Piranfar (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: